Mirae Asset Global Investments Co. Ltd. Acquires New Shares in Ascendis Pharma A/S $ASND

Mirae Asset Global Investments Co. Ltd. bought a new position in Ascendis Pharma A/S (NASDAQ:ASND) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 7,274 shares of the biotechnology company’s stock, valued at approximately $1,657,000.

Other institutional investors also recently modified their holdings of the company. Personal CFO Solutions LLC grew its holdings in shares of Ascendis Pharma A/S by 4.4% during the 1st quarter. Personal CFO Solutions LLC now owns 1,519 shares of the biotechnology company’s stock valued at $347,000 after acquiring an additional 64 shares in the last quarter. EverSource Wealth Advisors LLC increased its stake in shares of Ascendis Pharma A/S by 34.0% in the first quarter. EverSource Wealth Advisors LLC now owns 272 shares of the biotechnology company’s stock worth $62,000 after acquiring an additional 69 shares during the last quarter. ProShare Advisors LLC increased its stake in shares of Ascendis Pharma A/S by 5.6% in the third quarter. ProShare Advisors LLC now owns 2,134 shares of the biotechnology company’s stock worth $486,000 after acquiring an additional 113 shares during the last quarter. Allworth Financial LP raised its holdings in shares of Ascendis Pharma A/S by 103.4% during the second quarter. Allworth Financial LP now owns 240 shares of the biotechnology company’s stock worth $64,000 after acquiring an additional 122 shares in the last quarter. Finally, Parallel Advisors LLC raised its holdings in shares of Ascendis Pharma A/S by 94.9% during the first quarter. Parallel Advisors LLC now owns 304 shares of the biotechnology company’s stock worth $70,000 after acquiring an additional 148 shares in the last quarter.

Ascendis Pharma A/S Stock Performance

ASND stock opened at $256.82 on Friday. The company has a quick ratio of 2.32, a current ratio of 2.99 and a debt-to-equity ratio of 0.27. The company has a market capitalization of $16.02 billion, a price-to-earnings ratio of 19.92 and a beta of 0.40. Ascendis Pharma A/S has a 12 month low of $188.07 and a 12 month high of $282.15. The firm has a 50 day moving average of $242.50 and a two-hundred day moving average of $239.00.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings results on Friday, August 14th. The biotechnology company reported $1.03 EPS for the quarter, missing the consensus estimate of $1.71 by ($0.68). The business had revenue of $387.22 million for the quarter, compared to analyst estimates of $376.75 million. Ascendis Pharma A/S had a return on equity of 32.54% and a net margin of 70.99%. As a group, equities analysts anticipate that Ascendis Pharma A/S will post 3.43 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently issued reports on ASND shares. Weiss Ratings reissued a “hold (c)” rating on shares of Ascendis Pharma A/S in a research report on Tuesday, October 13th. TD Cowen reaffirmed a “buy” rating on shares of Ascendis Pharma A/S in a research report on Thursday, September 10th. BMO Capital Markets reaffirmed an “outperform” rating on shares of Ascendis Pharma A/S in a research report on Thursday, September 10th. Jefferies Financial Group cut their price target on Ascendis Pharma A/S from $333.00 to $330.00 and set a “buy” rating for the company in a research note on Monday, August 31st. Finally, Citigroup reduced their price target on Ascendis Pharma A/S from $360.00 to $330.00 and set a “buy” rating for the company in a report on Monday, October 26th. Nineteen investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $305.95.

Insiders Place Their Bets

In related news, SVP Mads Bodenhoff sold 3,000 shares of the company’s stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $270.19, for a total value of $810,570.00. Following the completion of the sale, the senior vice president directly owned 3,000 shares in the company, valued at approximately $810,570. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Jean-Jacques Bienaimé bought 2,000 shares of the stock in a transaction on Friday, August 14th. The shares were acquired at an average cost of $246.33 per share, for a total transaction of $492,660.00. Following the completion of the transaction, the director directly owned 2,900 shares of the company’s stock, valued at approximately $714,357. The trade was a 222.22% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 40.00% of the company’s stock.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S is a biopharmaceutical company headquartered in Denmark that develops medicines for rare diseases, with a focus on endocrinology. Founded in 2006, the company uses its TransCon technology platform to design therapies intended to provide sustained delivery of medicines.

Its commercial products include SKYTROFA (lonapegsomatropin), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a treatment for adults with hypoparathyroidism.